Up to 50 Critical Medicines Out of Stock in SA

The DA has requested a special parliamentary health committee meeting to investigate shortages in the public health system.

Updated on Nov. 4, 2026 in Healthcare

Bold flat-color editorial illustration of an empty institutional building facade with unlit windows, in deep red and cream, evoking shortages in the public health system. — The Democratic Alliance has asked Parliament's health committee to investigate shortages of up to 50 critical medicines, including treatments for high blood pressure and diabetes, in South Africa's public health system. AI Illustration. Upload story photo >

Live Poll

Do you trust your local public health clinics to reliably supply your prescribed medicines?

Up to 50 critical medicines are out of stock in South Africa's public health system, including chronic treatments for high blood pressure, diabetes, and high cholesterol. The Democratic Alliance has asked Parliament's health committee to investigate the shortages.

Why it matters

Patients reliant on public clinics for chronic medication face disruption to their treatment across the country. Some local manufacturers link the shortages to new SAHPRA regulations and the single exit price, which they say have weakened the local pharmaceutical industry.

The DA cites up to 50 critical medicines out of stock in the public system, while the national Department of Health has not released patient numbers or a list of affected medicines. The full scale of patients affected by the shortages remains unconfirmed.

The players

Democratic Alliance (DA)

The DA is a South African opposition party that has pressed the government on public health service delivery.

Michele Clarke

Michele Clarke is the DA's health spokesperson, leading the party's call for an investigation into medicine stock shortages.

South African Health Products Regulatory Authority (SAHPRA)

SAHPRA is South Africa's national regulator for medicines and medical devices, whose new regulations some local manufacturers blame for industry decline.

The details

The DA's health spokesperson, Michele Clarke, requested a special meeting of Parliament's health committee on 26 October and filed a PAIA request with the Department of Health on 28 October. The national department says there are supply constraints in some districts and facilities, while the Gauteng provincial department acknowledges supplier delays and changes to medicine contracts.

26 October 2026: DA requests a special parliamentary health committee meeting
28 October 2026: DA files a PAIA request with the Department of Health for stock-tracking reports covering April to October 2026

Industry Context

Some local manufacturers attribute the decline of the domestic pharmaceutical sector to SAHPRA's new regulations and the single exit price for medicines. The DA's current request places those policy effects under parliamentary scrutiny.

Patients on chronic treatment for blood pressure, diabetes, or high cholesterol may face gaps in supply at public facilities. The DA warns that substitute medicines can cause adverse reactions and that some patients may stop treatment altogether out of confusion.

The takeaway

Patients on chronic medication should confirm their supply with their clinic and avoid altering doses, such as splitting pills, without advice from a health professional. Stock disruptions tend to surface first at local facilities, so early reporting of gaps matters.